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Although it is generally accepted that psoriasis
is characterized by an increased rate of epidermal
regeneration and incomplete keratinization, the
mechanism underlying these defects is not well
understood. The therapeutic efficacy of cytotoxic
drugs has supported the theory of accelerated
epidermopoiesis, but has not given any clue to
the etiology of the disease (1, 2). Recent investiga-
tions have suggested that psoriasis is a metabolic
error and that the defect relates to the synthesis
of sulfur-containing compounds or complex
lipids (3).
Radio-isotope studies by Rothberg et al. have
shown that in the psoriatic lesion, there is ac-
celerated metabolic activity over that of the
normal epidermis (4). There may therefore be an
increased requirement for sulfur or, as indicated
by the biochemical studies of the psoriatic scale,
there may be abnormal utilization of sulfur-
containing metabolites. (5, 6, 7). In order to
elucidate this problem and to discover whether
lipid synthesis is implicated in the disease process,
it seemed desirable to utilize an agent, which
could have an effect on sulfur or lipid metabo-
lism.
In our present study, the bile-acid sequestrant,
cholestyramine was used for this purposef. Cho-
lestyramine is the chloride salt of a quaternary
ammonium anion exchange resin. It has a marked
affinity for bile-acids in vitro, exchanging chloride
for the acids and forming an insoluble complex
with them in the intestinal tract. When fed to
laboratory animals and human subjects, this
agent lowers serum cholesterol and promotes the
fecal excretion of bile-acids (8). Its recent use in
psoriasis has been based on theoretical considera-
tions, which will be the subject of discussion
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later in this paper. Since it has been presumed
that this agent would lower the intestinal reab-
sorption of taurine, derived from conjugated bile-
acids, the excretion of this sulphur-containing
amino-acid was followed during cholestyramine
administration. This was compared with the
taurine excretion levels during ACTH therapy
and UVL irradiation. At the same time, the effect
of cholestyramine on serum cholesterol and on
the absorption of vitamin K has been followed.
Clinical Trial
Pr&edure
Twelve patients with chronic psoriasis were
treated with the bile-acid sequestrant cholestyra-
mine. These patients received this resin over per-
iods varying from two to eleven months, though
therapy was not always continuous because sup-
plies were not available at all times. The
individual dose varied from 9.9—16.5 grams daily.
Seven of these patients were studied with relation
to taurine exretion. One case of generalized ex-
foligtive psoriasis, included in this group, received
injections of ACTH for a period which overlapped
the course of eholestyramine. Three other pa-
tients, also in the group, received ultra-violet
light over certain weeks of the trial period. No
local therapy was prescribed, except in the case of
exfoliative psoriasis, where the application of
vaseline was permitted. The effect of the intermit-
tent administration of a placebo, in place of the
resin, was followed in three cases.
Laboiatory Studies
(a) Taurine excretion. Samples of scale, feces and
urine were collected before the institution of the
experimental therapy and thereafter at specified
intervals. Estimations of taurine in the urine and
feces were made and expressed as milligrams ex-
creted in the 24 hourly specimen, except as
indicated. Since only one of the patients was
treated in hospital, close supervision of sample
collection was not possible. In cases where incom-
plete samples were presented, taurine was esti-
mated as milligrams per liter of urine or milligrams
per gram of feces. Facilities were not available for
the complete 24 hourly collection of exfoliated
scale, therefore taurine was calculated for each
gram of scale shed.
Feeal and scale extracts were prepared by a
modification of Garvin's method, in which samples
were homogenized with water and deproteinized
with triehloracetie acid (9). The deproteinized
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extracts and the urine samples (10 ml. of each)
were passed through chromatographic columns of
Dowex 50-x8 (200—400 mesh) in the hydrogen form.
This sulfonic acid exchange resin has the capacity
of removing amino compounds, which would inter-
fere with subsequent taurine analysis. The column
size was 10 x 1 cm. The effluent from the columns
was analyzed for its taurine content by two
methods. Sorbo's colorimetric method, involving
the reaction of taurine with ninhydrin was used
routinely for the urine specimens (10). It was also
used for the estimation of taurine in scale ex-
tracts. However, it was not found satisfactory for
the analysis of fecal extracts, since there were
interfering ninhydrin-positive substances present.
For the analysis of fecal extracts, a method was
developed, based on the specific color reaction of
taurine with o-phthalaldehyde (11). This method
was recently applied to urine and scale extracts
and results were comparable to Sorbo's method.
Chromatographic analysis was employed to
check the precision of the quantitative methods,
used in taurine estimation. Awapara's procedure
was followed with respect to the concentration of
column effluents (12). The concentrated samples
were applied to Whatman No. 1 papers, which
were developed by one dimensional and two di-
mensional technics. The solvent systems employed
included 77 per cent alcohol, Butanol: acetic acid:
water and methyl ethyl ketone: tert. butanol:
water: pyridine in the one dimensional method.
Ascending chromatography was carried out with
the first two solvents and descending with the
third. In the two dimensional chromatography,
butanol: acetic acid: water was used in the first
direction and this was followed by 2,4-lutidine
saturated with a phosphate buffer at pH 6.0, in
the second direction. The detection of the taurine
spots was achieved, a) with a ninhydrin spray and
b) by Curzon's method using o-phthalaldehyde
(13).(b) Cholesterol synthesis and vitamin K absorp-
tion. Serum cholesterol was estimated, in the se-
lected patients, before and at monthly intervals
after the institution of the trial (14).
The absorption of vitamin K was followed by
estimation of the prothrombin time. Estimations
were made before and during therapy, at three
weekly intervals, using commercial Simplastin
(Warner-Chilcott).
Results
Clinical Trial
Remission of the psoriasis has taken place in
all the patients treated with cholestyramine;
clearing being total in two cases and partial in
the others. The degree of clinical improvement is
analysed in Table I. The salient features in the
therapeutic response include an arrest in the
therapy
Subject
No. Age
TABLE I
The clinical response of 12 psoriatic patients to cholestyramine
Clinical features before therapy
Sex Estent
Therapy (Duration)(in months) Results
1
2
3
4
5
6
7
8
9
10
11
12
50
40
32
21
60
27
27
57
53
41
56
52
M
M
M
M
M
F
F
M
F
F
M
M
+++
++++
+++
++
++
+++
+++
+++
+++
+++
+++
++
Scale
++
+++
+++
++
+
++
++
++
++
++
+++
++
Pruritus
++
0
+
0
++
+
++
++
+++
++
++
0
Resin
5
11
11
6
5
3
4
2
2
2
2
2
Other
TJVL (1)
UVL (1)
ACTH (2
wks)
IJVL (2)
Extent
0
+
+
0
+
++
+
++
++
++
++
++
Scale
0
0
0
0
0
0
0
0
+
+
+
0
Pruritus
0
0
0
0
0
0
0
0
0
0
0
0
Key:
Extent
++++ 70-100
+++ 40-70
++ 10—40
+ under 10
Extent estimated as per cent of total body surface
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TABLE II
The Relationship of Cholestyrasnine Therapy to
Taurine Excretion in Psoriatic Subjects (7)
Range of Fecal Taurine Excretion
(mg./24 hours)
Befora therapy
During therapy
Control
Range of Urinary Taurine Excre-
tion (mg./24 hours)
Before therapy
During therapy
Control (Hubbard)
Control (Stein)
Psoriatic subjeats (Hubbard).
extension of the dermatosis, cessation of as-
sociated pruritus, diminution in sealing and paling
of lesions. In four patients, who had an associated
arthritis, pain was eontrollled, but no radiological
evidence of improvement has as yet been re-
corded. The initial clearing has been recorded in
five to ten days after the onset of therapy. The
dose required to permit the continued improve-
ment has varied in the individual patients. About
one week after the cessation of therapy, lesions
started to reappear, and this has also occurred
when a placebo was substituted for the drug.
Diminution in dosage below the effective level
has resulted in reactivation of the disease.
Side effects have been very slight and have
mainly been related to change in bowel function.
There has been initial diarrhea in two patients
and constipation in two others. One case reported
anal pruritus. There has been no evidence of
weight loss and no avitaminosis has been ob-
served.
Laboratory Studies
Increased fecal excretion of taurine has been
demonstrated during cholcstyramine therapy.
In the seven cases studied, it appears that the
maximal taurine excretion occurs during the time
of greatest clinical improvement. Although, it has
been shown that taurinc excretion decreases
rapidly after cessation of therapy, no correlation
has been obtained between the dosage of cho-
lestyramine and the taurine levels in the fcces.*
Cysteic acid has been detected, by chromato-
graphic methods, in the fecal extracts, from
psoriatic patients, prior to cholestyramine
therapy. It disappears during therapy and has not
With prolonged therapy, the fecal excretion of
taurine has tended to diminish and this has been
reflected in a lessening in the clinical response.
Increases in the urinary excretion of taurine,
during cholcstyramine therapy, have not been
demonstrated, nor has there been evidence of
change in the taurine level of the scale. However,
total daily collection of scale will be necessary,
before we can be sure of these latter findings.
(Table II)
Generalized ultraviolet light and also the
administration of ACTH induced increased out-
put of taurine in the urine. The initial response in
taurine excretion to the three therapeutic mo-
dalities is demonstrated for the case of exfoliative
psoriasis (Table III).
Dramatic changes in the serum cholesterol
levels of patients receiving cholestyramine were
not observed. However, with prolonged medica-
tion, a cholesterol lowering effect was noticeable.
Prolongation of the prothrombin time occurred
in patients on the higher dosage schedules. This
been found in the fecal extracts from normal sub-jects. The significance of this finding is not known
at present. Since cysteic acid forms colored com-
pounds with o-phthalaldehyde, it has to be re-
moved prior to taurine analysis. This problem will
be discussed in a subsequent paper, describing the
analytical methods, employed in our studies.
TABLE III
M4 35 CM /24 HOURS
AUTH 1]NITS505045403530252015105 00
TAU RI NE
EXCRETION
mgm/24 HOURS T.H. EXFOLIATIVE PSORIASIS
FECES
S URINE0—21
28—412
0—20 (no
medication)
47—195
40—273
36—154
86—294
17—185 (no
medication)
I I 2 3 4 5 6 7 8 9 10 II 12 13 14
DAYS OF TREATMENT
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was rapidly corrected by oral dosage of water
soluble vitamin K or by intramuscular injections
of this vitamin. (Table IV).
Discussion
The application of cholestyramine to the ex-
perimental therapy of psoriasis has been based
on the possible modes of action of the drug viz:
1) That cholestyramine might increase sulfur
excretion through an affinity for conjugated bile-
acids. Hence taurine would be eliminated in the
feces.
2) That it acts as a cholesterol lowering agent.
3) That this resin, by promoting the fecal
excretion of bile-acids, interferes with the absorp-
tion of a lipid-soluble nutrient.
With regard to the first hypothesis, it is in-
teresting that many of the agents used in the
treatment of psoriasis have been shown, either in
experimental animals or in normal subjects, to
promote taurine excretion. These agents include
ionizing radiations, ACTH and certain cytotoxic
agents, e.g. eolehicine (15, 16, 17). No previous
attempt has been made to correlate the clinical
effectiveness of these modalities with the taurine
levels of the urine, feces and scale.
It has been demonstrated that cholestyramine
may ameliorate the course of psoriasis. Improve-
ment in the clinical condition has been associated
with an increase in the fecal excretion of taurine.
The free fecal taurine may be derived from
taurine-conjugated bile-acids, by microbiological
action in the large intestine.
It has been generally assumed that taurine is
an end product of sulfur metabolism, though
recent studies have indicated that it may have
an active biochemical function (18). However, it
is accepted that cysteiae and cystine undergo
conversion to taurine in the animal body (19).
Proof of the degradation of methionine sulfur to
taurine sulfur has been obtained in the dog and
in the rat (20). The reversible interconversion
of cysteine and cystine and the one-way deriva-
tion of cysteine and cystine sulfur from methio-
nine sulfur are well known chemical reactions.
Several pathways for the conversion of these sub-
stances to taurine have been postulated, but
today only two are favored viz: (21)
(1) Cysteine —, cysteine sulfinic acid —
/3 amino ethane sulfinic acid --s taurine.
(2) Cysteinc —÷ cysteine sulfinic acid —*
cysteic acid —s taurine.
The first of these two routes is quantitatively
much more significant.
The demonstration that increased fecal and
urinary excretion of taurine follows the adminis-
tration of certain therapeutic agents to psoriatic
patients, does not necessarily reflect a depletion
of preformed tissue taurine. The theory is sug-
gested that the increased taurine excretion is
evidence of catabolic processes, involving the
sulfur containing amino acids. Yet, it has been
shown in animal experiments that depletion of
sulfhydryl compounds, by cholic acid feeding,
will reduce the taurine response to whole body
TABLE IV
Effect of cholestyramine on serum cholesterol and prothrombin activity
S
1
2
3
4
5
6
7
8
9
10
11
12
50
40
32
21
60
27
27
57
53
41
56
52
Subject
Age Sex
Daily Dose
in Grams
Duration
Therany
Months
Serum cholesterol
Mgm Per cent
Prsthrombin Activity
(% normal)
Initial Final Initial Final
M
M
M
M
M
F
F
M
F
F
M
M
13.2
13.2—16.5
13.2—16.5
9.9—13.2
9.9
9.9—13.2
13.2—16.5
6.6—13.2
6.6—9.9
13.2
13.2
13.2—16.5
5
11
11
6
5
3
4
2
2
2
2
2
230
204
220
169
220
174
237
276
226
204
205
160
217
110
215
142
223
151
212
218
214
182
170
152
100
79
100
100
75
100
80
76
—
100
100
100
100
45
18
100
85
100
90
100
—
70
100
—
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irradiation (22). By analogy, one may suppose
that the usefulness of eholestyramine will be
limited to the availability of sulphur containing
compounds, which can be degraded to taurine
and indeed, there may be further limitation, due
to the body's attempt to conserve sulfur by bile-
acid conjugation with glycine.
Supposing that epidermal retention of sulfur
containing compounds is essential to the patho-
genesis of psoriasis, then effective therapy might
require a stimulus to the catabolism of such sub-
stances, plus the induction of the excretion of
their metabolites, by such an agent as chol-
lestyramine.
However, in this ear]y phase of the investiga-
tion, it is not possible to be sure whether the
action of cholestyramine is limited to its effect on
taurine metabolism. Its fundamental property
may be an effect on the absorption of a lipid
soluble nutrient, as yet undefined. We know that
a glycolipid is closely associated with the normal
process of keratinixation (23) and perhaps the
bile-acid sequestrant may have an action on its
formation.
It is hoped that further research will elucidate
these problems and that cholestyramine may
prove a useful tool in our studies.
Summery
The bile-acid sequestrant cholestyramine has
been used in the experimental therapy of psoria-
sis. Twelve patients, suffering from chronic
psoriasis, have been given this drug and evidence
of increased fecal excretion of taurine has been
obtained. This effect has been compared with the
increased urinary excretion of taurine induced by
such agents as ultraviolet light and ACTH.
Other properties of the drug have been followed,
including its effect on serum cholesterol levels
and vitamin K absorption. The beneficial re-
sponse of the patients to this agent has been
discussed in relation to its mode of action and
to the pathogenesis of the disease.
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DISCUSSION
DR. PETER FLESCH, Philadelphia, Pa.: I would
like to compliment Dr. Roe for this beautiful
piece of work. She did not have the time to talk
about the difficulties in the administration of this
compound.
DR. DAPHNE ANDERSON ROE, (in closing): I
do not know that Dr. Flesch's comment requires
an answer.
I would just like to say a word about the ad-
ministration of this drug. It is supplied in two
forms, as a powder which has a very strong
amine smell which is difficult to disguise, and
now very recently, as a tablet 750 mgm which
is more palatable. However, the number of
tablets that have to be consumed per day is
rather high.
